New Bruxism Study Findings Recently Were Reported by Researchers at Fluminense Federal University (Use of Botulinum Neurotoxin Type a In the Management of Primary Bruxism In Adults: an Updated Systematic Review).

A recent systematic review conducted by researchers at Fluminense Federal University in Niteroi, Brazil, explored the use of Botulinum Neurotoxin Type A (BoNT-A) as a treatment for primary bruxism in adults. The study found that injecting BoNT-A into the masseter muscles resulted in a reduction of bruxism symptoms in 211 participants across 11 randomized clinical trials. The research concluded that doses lower than 25U applied exclusively in the masseter muscles were effective in reducing symptoms. Further studies are needed to establish a protocol for this off-label use of BoNT-A. [Extracted from the article]